AION Labs Launches Second Startup Focused on AI-Enabled Antibody Development

in Israel AION Labs, a partnership between global pharmaceutical and technology companies to discover drugs through AI, has announced the launch of its second startup, DenovAI.

DenovAI will develop an AI-enabled biophysical computing platform that can detect potential antibodies that target specific epitopes (the portion of an antigen molecule recognized by the immune system to which the antibody attaches). The company said the platform will develop antibodies from scratch and then propose candidates that are likely to make effective drugs.

AION Labs was built as part of a government tender and includes pharmaceutical giants AstraZeneca, Merck, Pfizer and Teva, as well as venture capital firm Israel Biotech Fund, strategic partner Amazon Web Services, and German independent research institute Bio Med X.

Financial and pharmaceutical data for machine learning development and model training will be provided to DenovAI by AION Labs.

“We have made significant strides in the field of therapeutic antibodies, but the process of developing new drugs is incredibly slow, extremely expensive and inefficient. With the support of AION Labs and its partners, we hope to develop a cutting-edge solution that will disrupt the entire field, reducing opening times from months to days. And it could greatly expand the potential of antibody therapy to treat many other diseases,” Dr. Kashif Sadiq, founder and CEO of DenovAI, said in a statement.

BIG TREND

AION Labs announced its first startup last year, dubbed OMEC.AI, which aims to provide an artificial intelligence-enabled computing platform that will help researchers assess drug candidate clinical trial readiness, identify hidden safety flaws, and propose experiments to address any identified gaps.

“What we’re trying to achieve at AION Labs as a whole…is building great independent AI-based start-ups for the biotech field so that we can help scientists and researchers — not replace them, but really empower them by bringing in new technologies. opportunities so that they can streamline the entire process of drug discovery and development,” This was stated by the CEO of AION Labs Mati Gil. MobiHealthNews in September.

Other companies using AI tools for drug discovery include a drug research platform. Insilico Medicine and Healx, a British medical technology company that uses AI to speed up drug discovery and treat rare diseases.

Content Source

Dallas Press News – Latest News:
Dallas Local News || Fort Worth Local News | Texas State News || Crime and Safety News || National news || Business News || Health News

texasstandard.news contributed to this report.

Related Articles

Back to top button